Discovery and optimization of tetramethylpiperidinyl benzamides as inhibitors of EZH2

ACS Medicinal Chemistry Letters

Volumn 5, Issue 4, 2014, Pages 378-383

  Nasveschuk, Christopher G ^a   Gagnon, Alexandre ^a,b   Garapaty Rao, Shivani ^a   Balasubramanian, Srividya ^a   Campbell, Robert ^a   Lee, Christina ^a   Zhao, Feng ^a   Bergeron, Louise ^a   Cummings, Richard ^a   Trojer, Patrick ^a   Audia, James E ^a   Albrecht, Brian K ^a   Harmange, Jean Christophe P ^a  

^a Department of Structural Biology   (United States)

^b UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

Author keywords

diphenylether; EZH2; KARPAS 422; methyltransferase; PRC2; tetramethylpiperidine

Indexed keywords

BENZAMIDE DERIVATIVE; EPZ 6438; GSK 126; PROTEIN INHIBITOR; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR EZH2 INHIBITOR; UNC 1999; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 84898034702     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml400494b     Document Type: Article

References (25)

1. Margueron, R.; Reinberg, D. The Polycomb Complex PRC2 and Its Mark in Life Nature 2011, 469, 343-349
2. Kleer, C. G.; Cao, Q.; Varambally, S.; Shen, R.; Ota, I.; Tomlins, S. A.; Ghosh, D.; Sewalt, R. G.; Otte, A. P.; Hayes, D. F.; Sabel, M. S.; Livant, D.; Weiss, S. J.; Rubin, M. A.; Chinnaiyan, A. M. EZH2 is a Marker of Aggressive Breast Cancer and Promotes Neoplastic Transformation of Breast Epithelial Cells Proc. Natl. Acad. Sci. 2003, 100, 11606-11611
3. Varambally, S.; Dhanasekaran, S. M.; Zhou, M.; Barrette, T. R.; Kumar-Sinha, C.; Sanda, M. G.; Ghosh, D.; Pienta, K. J.; Sewalt, R. G.; Otte, A. P.; Rubin, M. A.; Chinnaiyan, A. M. The Polycomb Group Protein EZH2 is Involved in Progression of Prostate Cancer Nature 2002, 419, 624-629
4. Majer, C. R.; Jin, L.; Scott, M. P.; Knutson, S. K.; Kuntz, K. W.; Keilhack, H.; Smith, J. J.; Moyer, M. P.; Richon, V. M.; Copeland, R. A.; Wigle, T. J. A687V EZH2 Is a Gain-of-Function Mutation Found in Lymphoma Patients FEBS Lett. 2012, 586, 3448-3451
5. McCabe, M. T.; Graves, A. P.; Ganji, G.; Diaz, E.; Halsey, W. S.; Jiang, Y.; Smitheman, K. N.; Ott, H. M.; Pappalardi, M. B.; Allen, K. E.; Stephanie, B. C.; Della Pietra, A., III; Dul, E.; Hughes, A. M.; Gilbert, S. A.; Thrall, S. A.; Tummino, P. J. Mutation of A677 in Histone Methyltransferase EZH2 in Human B-Cell Lymphoma Promotes Hypertrimethylation of Histone H3 on Lysine 27 (H3K27) Proc. Natl. Acad. Sci. 2012, 109, 2989-2994
6. Sneeringer, C. J.; Scott, M. P.; Kuntz, K. W.; Knutson, S. K.; Pollock, R. M.; Richon, V. M.; Copeland, R. A. Coordinated Activities of Wild-Type Plus Mutant EZH2 Drive Tumor-Associated Hypertrimethylation of Lysine 27 on Histone H3 (H3K27) in Human B-Cell Lymphomas Proc. Natl. Acad. Sci. 2010, 107, 20980-20985
7. Wigle, T. J.; Knutson, S. K.; Jin, L.; Kuntz, K. W.; Pollock, R. M.; Richon, V. M.; Copeland, R. A.; Scott, M. P. The Y641C Mutation of EZH2 Alters Substrate Specificity for Histone H3 Lysine 27 Methylation States FEBS Lett. 2011, 585, 3011-3014
8. Yap, D. B.; Chu, J.; Berg, T.; Schapira, M.; Cheng, S. W.; Moradian, A.; Morin, R. D.; Mungall, A. J.; Meissner, B.; Boyle, M.; Marquez, V. E.; Marra, M. A.; Gascoyne, R. D.; Humphries, R. K.; Arrowsmith, C. H.; Morin, G. B.; Aparicio, S. A. J. R. Somatic Mutations at EZH2 Y641 Act Dominantly Through a Mechanism of Selectively Altered PRC2 Catalytic Activity, to Increase H3K27 Trimethylation Blood 2011, 117, 2451-2459
9. Diaz, E.; Machutta, C. A.; Chen, S.; Jiang, Y.; Nixon, C.; Hofmann, G.; Key, D.; Sweitzer, S.; Patel, M.; Wu, Z.; Creasy, C. L.; Kruger, R. G.; LaFrance, L.; Verma, S. K.; Pappalardi, M. B.; Le, B.; Van Aller, G. S.; McCabe, M. T.; Tummino, P. J.; Pope, A. J.; Thrall, S. H.; Schwartz, B.; Brandt, M. Development and Validation of Reagents and Assays for EZH2 Peptide and Nucleosome High-Throughput Screens J. Biomol. Screening 2012, 17, 1279-1292
10. Knutson, S. K.; Wigle, T. J.; Warholic, N. M.; Sneeringer, C. J.; Allain, C. J.; Klaus, C. R.; Sacks, J. D.; Raimondi, A.; Majer, C. R.; Song, J.; Scott, M. P.; Jin, L.; Smith, J. J.; Olhava, E. J.; Chesworth, R.; Moyer, M. P.; Richon, V. M.; Copeland, R. A.; Keilhack, H.; Pollock, R. M.; Kuntz, K. W. A Selective Inhibitor of EZH2 Blocks H3K27 Methylation and Kills Mutant Lymphoma Cells Nat. Chem. Biol. 2012, 8, 890-896
11. McCabe, M. T.; Ott, H. M.; Ganji, G.; Korenchuk, S.; Thompson, C.; Van Aller, G. S.; Liu, Y.; Graves, A. P.; Della Pietra, A., III; Diaz, E.; LaFrance, L. V.; Mellinger, M.; Duquenne, C.; Tian, X.; Kruger, R. G.; McHugh, C. F.; Brandt, M.; Miller, W. H.; Dhanak, D.; Verma, S. K.; Tummino, P. J.; Creasy, C. L. EZH2 Inhibition as a Therapeutic Strategy for Lymphoma with EZH2-Activating Mutations Nature 2012, 492, 108-112
12. Qi, W.; Chan, H.; Teng, L.; Li, L.; Chuai, S.; Zhang, R.; Zeng, J.; Li, M.; Fan, H.; Lin, Y.; Gu, J.; Ardayfio, O.; Zhang, J.-H.; Yan, X.; Fang, J.; Mi, Y.; Zhang, M.; Zhou, T.; Feng, G.; Chen, Z.; Li, G.; Yang, T.; Zhao, K.; Liu, X.; Yu, Z.; Lu, C.; Atadja, P.; Li, E. Selective Inhibition of EZH2 by a Small Molecule Inhibitor Blocks Tumor Cell Proliferation Proc. Natl. Acad. Sci. 2012, 109, 21360-21365
13. Verma, S. K.; Tian, X.; LaFrance, L. V.; Duquenne, C.; Suarez, D. P.; Newlander, K. A.; Romeril, S. P.; Burgess, J. L.; Grant, S. W.; Brackley, J. A.; Graves, A. P.; Scherzer, D. A.; Shu, A.; Thompson, C.; Ott, H. M.; Van Aller, G. S.; Machutta, C. A.; Diaz, E.; Jiang, Y.; Johnson, N. W.; Knight, S. D.; Kruger, R. G.; McCabe, M. T.; Dhanak, D.; Tummino, P. J.; Creasy, C. L.; Miller, W. H. Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2 ACS Med. Chem. Lett. 2012, 3, 1091-1096
14. Konze, K. D.; Ma, A.; Li, F.; Barsyte-Lovejoy, D.; Parton, T.; MacNevin, C. J.; Liu, F.; Gao, C.; Huang, X.-P.; Kuznetsova, E.; Rougie, M.; Jiang, A.; Pattenden, S. G.; Norris, J. L.; James, L. I.; Roth, B. L.; Brown, P. J.; Frye, S. V.; Arrowsmith, C. H.; Hahn, K. M.; Wang, G. G.; Vedadi, M.; Jin, J. An Orally Bioavailable Chemical Probe of the Lysine Methyltransferases EZH2 and EZH1 ACS Chem. Biol. 2013, 8, 1324-1334
15. Kuntz, K. W.; Chesworth, R.; Duncan, K. W.; Keilhack, H.; Warholic, N.; Klaus, C.; Kathleen, S. K.; Wigle, T. J. N.; Seki, M.; Shirotori, S.; Kawano, S. Aryl- or Heteroaryl-Substituted Benzene Compounds. U.S. Patent Appl. 20130123234, 2013.
16. Sweis, R. F.; Michaelides, M. R. Chapter Thirteen: Recent Advances in Small-Molecule Modulation of Epigenetic Targets: Discovery and Development of Histone Methyltransferase and Bromodomain Inhibitors Annu. Rep. Med. Chem. 2013, 48, 185-203
17. Shivani Garapaty-Rao, S.; Nasveschuk, C. G.; Gagnon, A.; Chan, E. Y.; Sandy, P.; Busby, J.; Balasubramanian, S.; Campbell, R.; Zhao, F.; Bergeron, L.; Audia, J. E.; Albrecht, B. K.; Harmange, J.-C.; Cummings, R.; Trojer, P. Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth Chem. Biol. 2013, 20, 1329-1339
18. Shoichet, B. K. Interpreting Steep Dose-Response Curves in Early Inhibitor Discovery J. Med. Chem. 2006, 49, 7274-7277
19. 50) of an Enzymatic Reaction Biochem. Pharmacol. 1973, 22, 3099-3108
20. Shultz, M. D. Improving the Plausibility of Success with Inefficient Metrics Bioorg. Med. Chem. Lett. 2013, 23, 5980-5991
21. Shultz, M. D. The Thermodynamic Basis for the Use of Lipophilic Efficiency (LipE) in Enthalpic Optimizations Bioorg. Med. Chem. Lett. 2013, 23, 5992-6000
22. Dahlgard, M.; Brewster, R. Q. Absorption Spectra of Some Highly Substituted Diaryl Ethers J. Am. Chem. Soc. 1958, 80, 5861-5863
23. Gusakova, N. N.; Pankratov, A. N.; Fedorov, E. E.; Mushtakova, S. P.; Gribov, L. A. Calculation of the Conformation of Diphenylamine and its ortho-and para -Nitro-Derivatives by the Method of Atom-Atom Potentials J. Struct. Chem. 1981, 22, 341-345
24. Brameld, K. A.; Kuhn, B.; Reuter, D. C.; Stahl, M. Small Molecule Conformational Preferences Derived from Crystal Structure Data. A Medicinal Chemistry Focused Analysis J. Chem. Inf. Model. 2008, 48, 1-24
25. Thomas, V. H.; Bhattachar, S.; Hitchingham, L.; Zocharski, P.; Naath, M.; Surendran, N.; Stoner, C. L.; El-Kattan, A. The Road Map to Oral Bioavailability: An Industrial Perspective Expert Opin. Drug Metab. Toxicol. 2006, 2, 591-608